H.C. Wainwright Bullish on Genmab A/S (GMAB) on Robust Sales for DARZALEX
- Finance
ThePostMaster- 0
- 4 minutes read
Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025.
The company on January 21 reported a significant increase in net sales of DARZALEX in 2025. Worldwide net sales of DARZALEX reached $14.351 billion in 2025, up from $11.670 billion in 2024. More than half of the worldwide sales (around $8.266 billion) came from the US, while the remaining $6.085 billion came from the rest of the world.
Genmab does not sell the drug directly. Instead, they have licensed it exclusively to Johnson & Johnson and earn royalties on all worldwide net sales. During the first nine months of 2025 (ending September 30, 2025), Genmab A/S (NASDAQ:GMAB) received $2.219 billion in total Royalty revenue, which was up significantly from $1.802 billion in the first nine months of 2024. Management attributed the 23% year-over-year increase to higher net sales of DARZALEX and Kesimpta.
Before Johnson & Johnson reported net sales, management was anticipating full-year DARZALEX royalties to be in the range of $2.3 billion – $2.4 billion. This estimation was based on DARZALEX 2025 net sales of $13.7 billion – $14.1 billion. Since the actual net sales ($14.351 billion) exceed the top end of management’s guidance, the royalties are also expected to surpass the $2.4 billion mark.
Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotechnology company that specializes in creating and developing antibody therapeutics, primarily for cancer treatment. The company co-developed blockbuster drugs like DARZALEX (for multiple myeloma), Kesimpta (for multiple sclerosis), and TEPEZZA (for thyroid eye disease), earning royalties through licenses to partners like Johnson & Johnson.
While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
